Prognostic Role of M6A-Associated Immune Genes and Cluster-Related Tumor Microenvironment Analysis: A Multi-Omics Practice in Stomach Adenocarcinoma

Na Luo\textsuperscript{1}, Min Fu\textsuperscript{1}, Yiling Zhang\textsuperscript{1}, Xiaoyu Li\textsuperscript{1}, Wenjun Zhu\textsuperscript{1}, Feng Yang\textsuperscript{1}, Ziqi Chen\textsuperscript{1}, Qi Mei\textsuperscript{1}, Xiaohong Peng\textsuperscript{1}, Lulu Shen\textsuperscript{2}, Yuanyuan Zhang\textsuperscript{1,\ast}, Qianxia Li\textsuperscript{1,\ast} and Guangyuan Hu\textsuperscript{1,\ast}\textsuperscript{†}

\textsuperscript{1}Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, \textsuperscript{2}Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

\textsuperscript{\ast}Correspondence: Yuanyuan Zhang
z1731224978163.com
Qianxia Li
qianx110@163.com
Guangyuan Hu
h.g.y.121@163.com
\textsuperscript{†}Guangyuanhu, orcid.org/0000-0002-8060-4917

N6-methylandrostenedione (m6A) methylation plays a very important role in the development of malignant tumors. The immune system is the key point in the progression of tumors, particularly in terms of tumor treatment and drug resistance. Tumor immunotherapy has now become a hot spot and a new approach for tumor treatment. However, as far as the stomach adenocarcinoma (STAD) is concerned, the in-depth research is still a gap in the m6A-associated immune markers. The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases is extremely important for our research, where we obtained gene mutation, gene expression data and relevant clinical information of STAD patients. Firstly, the samples from GEO were used as external validation groups, while the TCGA samples were divided into a training group and an internal validation group randomly. Using the way of Single factor COX-LASSO- and multi-factor Cox to construct the prognostic model. Then, all samples were subjected to cluster analysis to generate high and low expression groups of immune gene. Meanwhile, we also collected the correlation between these types and tumor microenvironment. On this basis, a web version of the dynamic nomogram APP was developed. In addition, we performed microenvironmental correlation, copy number variation and mutation analyses for model genes. The prognostic model for STAD developed here demonstrated a very strong predictive ability. The results of cluster analysis manifested that the immune gene low expression group had lower survival rate and higher degree of immune infiltration. Moreover, the immune gene low expression group was associated with lower survival rates and a higher degree of immune infiltration. Gene set enrichment analysis suggested that the potential mechanism might be related to the activation of immunosuppressive functions and multiple signaling pathways. Correspondingly, the web version of the

Abbreviations: AUC, Area under the curve; GEO, Gene Expression Omnibus; GO, Gene Ontology; GSEA, Gene Set Enrichment Analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; LASSO, Least absolute shrinkage and selection operator; ROC, Receiver operating characteristic; ssGSEA, Single Sample Gene Set Enrichment Analysis; TCGA, The Cancer Genome Atlas.
INTRODUCTION

Stomach adenocarcinoma (STAD) is one of the leading malignancies contributing to the health burden as well as being the third leading cause of cancer deaths worldwide (Bray et al., 2018; Ferlay et al., 2019). Surgery is the main curative treatment for gastric cancer. However, as 80–90% of gastric cancer patients are already in the advanced stage at initial diagnosis, that’s almost impossible to cure (Wagner et al., 2010; Smyth et al., 2020). In recent years, with significant advances in new therapeutic strategies including chemotherapeutic agents, novel targeted agents and immunotherapeutic agents for patients with STAD, the overall efficacy and survival have improved, but the overall survival of patients is still not optimistic. As not all patients are responding to existing therapies based on recognized biomarkers (Chau, 2017; Song et al., 2017). Therefore, the further exploration of new markers which is leading to poor prognosis of STAD, classifying patients with different prognosis and enhancing the accuracy of predicting patient prognosis, is a positive significance to further improve early screening and treatment of STAD.

The study of N6-methyladenosine (m6A) has become more popular in recent years, leading to an increasing understanding on it. The N6-methyladenosine (m6A) methylation process includes three major methylation enzymes: methyltransferase (Writer), demethylase (Eraser), and methylation resolution protein (Reader) (Dominissini et al., 2012; Tong et al., 2018). m6A is involved in the regulation of genes at the transcriptional and post-transcriptional levels, which is necessary for cell survival and functional integrity (Yadav et al., 2018). Furthermore, m6A can be involved in tumorigenesis by regulating the expression of the tumor-associated genes BRD4, MYC, SOCS2, and EGFR (Vu et al., 2017; Yan et al., 2018; He et al., 2019; Lin et al., 2019). N6-methyladenosine (m6A) RNA methylation is linked to tumorigenesis and progression, which is regulated dynamically by m6A RNA methylation regulators (Weng et al., 2018; Zaccara et al., 2019; Wang et al., 2020a; Wang et al., 2020b; Chokkalla et al., 2020; Zhang et al., 2020). Studies have shown that there is a correlation between m6A and prognosis in STAD patients, and the m6A status is significantly connected to STAD tumor onset and progression. Li et al. have shown that the expression of FTO and ALKBH1 correlates with prognosis in STAD patients based on TCGA database exploration (Li et al., 2019). BATF2 regulates STAD progression via the METTL3, which provides a potential prognostic and therapeutic target for STAD therapy (Xie et al., 2020). METTL3 promotes angiogenesis and increases glycolysis via activation of the AKT signaling pathway (Wang et al., 2020c). HBXIP exerts a pro-cancer cell invasion role through METTL3-mediated modification of MYC mRNA m6A (Yang et al., 2020). Knockdown of METTL14 promotes STAD malignant progression via activation of the Wnt/Pi3K-AKT axis (Zhang et al., 2019). In addition, the characteristics of m6A RNA methylation for risk stratification can be utilized as an index of independent prognosis for overall survival (OS) in STAD (Mo et al., 2020). Additionally, PD1/PD-L1 checkpoint blockade is controlled by the m6A reader YTHDF1 and eraser FTO. Therefore, m6A modulators may be promising sites for anti-cancer immunotherapy (Han et al., 2019; Yang et al., 2019). Moreover, high anti-PD-1/L1 immunotherapy response and elevated neoantigen load was associated with a decreased m6Ascore in STAD patients (Zhang et al., 2020). In consequence, it is of great significance to study the role of m6A-regulated genes and their related pathways in immunotherapy for improving the efficacy and survival rate of immunotherapy in patients with STAD.

With the development of immunotherapy, various elements of the immune system including the immune microenvironment of tumor, immune-related genes, and immune cells have been found to play an important roles in the pathophysiology of tumors (O’Donnell et al., 2019; Atsavaprance et al., 2021; El-Mayta et al., 2021). The study of immunotherapy in STAD has attracted considerable increasing attention. Molecular characterization of STAD analyzed by the TCGA research network has shown increased expression of PD-L1 in a subpopulation of EBVs that account for 15% of STAD tumors (Comprehensive molecular characterization of gastric, 2014). In addition, it was shown that PD-L1 is expressed in both STAD cells and immune stroma. Surprisingly, Elizabeth et al. showed that increased CD8 infiltration was associated with shorter OS in STAD patients, and suggesting that adaptive immune tolerance mechanisms may be occurring (Thompson et al., 2017). Nivolumab and pembrolizumab are available for advanced gastric cancer patients (Noguchi et al., 2000; Janjigian et al., 2020). HER2-directed antibody-drug coupling, Disitamab vedotin (RC48), significantly enhanced antitumor response when combined with PD-1/PD-L1 immune checkpoint inhibitors, which was concomitant with immunomarker activation and substantial T-cell infiltration (Huang et al., 2022). Therefore, significant
therapeutic advantages and clinical benefits may emerge from the combination with immunotherapy in the treatment of gastric adenocarcinoma in the future.

Research showed that m6A plays an essential role in regulating and modifying viral RNA expression. At the same time, m6A scores have been used to forecast the effect of anti-PD-1/L1 immunotherapy. M6A is thus a reliable biomarker for both prognosis and evaluation of clinical response to immunotherapy (Zhang et al., 2020; Jin et al., 2021).

After downloading multiple public datasets, we used single-factor Cox regression, LASSO, and multi-factor Cox regression analyses to build a prognostic model with the basis of m6A-associated immune-related genes, and successfully created a web version of the dynamic nomogram app (Geng et al., 2020). Then, the correlations between the two types and the tumor microenvironment and m6A score were calculated. Additionally, the findings of enrichment analysis further revealed the potential immunosuppressive mechanism. Further, we performed correlation analysis of immune subtypes, clinical stage, as well as the microenvironment for model genes. Finally, the biological role of RAB19 in STAD cells was revealed.

METHODS

Data Collection and Variance Analysis

The gene expression dataset (HTSeq-FPKM), clinical information, and data related to mutation experiments for stomach adenocarcinoma (STAD) were obtained from The Cancer Genome Atlas (TCGA). The platform file (GPL6947-13512) and the STAD probe matrix file (GSE84433_series_matrix) were also downloaded from the GEO website as an external validation set. M6A regulatory genes were obtained from previously published literature (Xu et al., 2020). Here, we have extracted the immune-related genes (IRGs), which were contained in the Gene Set Enrichment Analysis (GSEA). All data were pretreated using the limma and sva packages. All samples were obtained via surgical excision of tissues from primary stomach adenocarcinoma patients.

First, we figured out the correlations between immune genes and m6A-regulated genes by using wilcox. test function and screened the results to obtain m6A-associated immune genes ($p$-value < 0.05 and $|\text{correlation coefficient}| > 0.4$) for subsequent analyses. Next, the corresponding hazard ratio (HR) values and $p$-values were obtained after survival analysis for m6A-regulated genes with univariate Cox analysis and the Kaplan-Meier method. An m6A prognostic network and co-expression network for m6A-regulated genes and immune genes were plotted using the igraph package ($|\text{correlation coefficient}| > 0.6$). Finally, the R package—limma was regarded as a tool to identify differential expression m6A-associated immune genes between normal and tumor groups [false discovery rate (FDR) < 0.05 and $|\log\text{fold change (FC)}| > 0.5$]; the results are presented in the form of a heat map.

Construction of Prognostic Model, Mutation Analysis, and Dynamic Nomogram

We randomly divided TCGA-STAD samples into two groups for training and internal validation, while corresponding GEO samples were used as external validation group. In the training group, we used the classical single variable cox model for regression, LASSO algorithm, and multiple variable Cox stepwise regression analyses to obtain the m6A-associated immune genes that had statistically significant effects on prognosis ($p < 0.05$). Moreover, in order to optimize the prognostic model, we removed highly correlated genes. Based on the median risk score of the training group as the cutoff value, all samples were separated into two groups, the high-risk group and the low-risk group, and to test the predictive capability of this model, our authors plotted survival curves and receiver operating characteristic (ROC) curves.

After the construction of the prognostic model, we visualized mutation waterfall plots by using the Maftools package for the high-risk and low-risk groups. Next, in the two groups, the effects of mutational load on survival were calculated.

The clinical translation value of our prognostic model will be enhanced by the download of the DynNom package, and the package exists can help us create the corresponding web-based dynamic column chart app that allows rapid and accurate determination of patient prognosis.

ssGSEA Analysis and Cluster Typing

For TCGA and GEO samples, in each sample, ssGSEA was used to calculate the contents of 23 immune cells using the Gsva package. All samples were clustered separately via using the Consensus Cluster Plus package based on the m6A-associated immune genes that affect prognosis ($p < 0.05$) to generate groups with high immune gene expression and low these gene expression. Based on the groups’ results, heat maps, violin plots, and microenvironment survival curves of tumors were plotted for the two immune gene expression groups to visualize the correlation between m6A-associated immune genes and immunity. The Org. Hs.eg.db R package was used to plot multi-GSEA enrichment curves. And the curves were based on five GO terms (gene ontology) of significant enrichment for the immune gene high-expression group, which was compared with the immune gene low-expression group, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways ($p < 0.05$).

Comprehensive Analysis for Model Genes

Firstly, we determined the correlations of individual model genes with immune subtypes, clinical stage, stem cell indices, and tumor microenvironment parameters. Furthermore, for model genes, the Tumor Immune Estimation Resource (TIMER) databases were used to calculate and analyze the copy number variation (CNV) frequency levels and the relationship between the immune cell infiltration of individual cells levels and the CNV. Finally, the mutation frequencies and structural domain mutations of model genes was downloaded from the cBioportal databases.

Drug Sensitivity Analysis

To investigate the effect of prognostic models on the sensitivity of drugs, two sets of data, FDA-approved drug sensitivity-related
and transcriptomic data were obtained from a database, which is called CellMiner database. The related link is https://discover.nci.nih.gov/cellminer/. In order to analyze gene expression and drug sensitivity, the Pearson correlation test was applied. Subsequently, the association with low-risk and high-risk populations in our prognostic model, as well as STAD-related drugs was analyzed using the “pROphetic” R package, and box plots were drawn.

Cell Lines and siRNA and Plasmid Transfection
GES one Normal Gastric Epithelium Cell Line, STAD cell lines SUN-216, SGC-7901, AGS, N87, BGC-823 and HGC-27 were purchased from The American Type Culture Collection, which is also known as the ATCC. And RPMI 1640 medium (HyClone, United States) was used to culture these cell lines, along with 10% fetal bovine serum (FBS, Gibco, United States) in 5% CO2. Equally important, all of them are at 37°C. RiboBio (Guangzhou, China) synthesized SiRNA and pcDNA3.1-RAB19. And as described in the production instructions, they were successfully transfected into our target with HighGene plus transfection reagent, which is bought from Abconlal, Wuhan, China.

qRT-PCR
The reverse transcription was performed by Hi Script II QRT SuperMix (Vazyme, China), and the RNA extraction from our cells using the TRIzol reagent (TaKaRa, Japan). Just like any other lab, we utilized Vazyme’s ChamQ Universal SYBR qPCR Master Mix (China) to perform qRT-PCR. The RAB19’s primer sequences were 5′-GTCCATCCCTCAGTGATTCA-3′ (forward) and 5′-GCATCCTCGAAGGACGTG-3′ (reverse), and the primers sequences for the internal reference gene β-actin were 5′-GACAGTCAGCCGCATCTTCT-3′ (forward) and 5′-GGGCCAAATACGCACAAATC-3′ (reverse). Here, we set β-actin as an internal control for this study.

Cell Counting Kit-8 Viability Detection
Cells (3,000 cells/well) were seeded in 96-well plates overnight for attachment. Then 100 µl per well FBS- free medium with 10% CCK8 (Bio-sharp, Hefei, China) was used instead incubating the cells for 1 h at 37°C. Microplate reader (BioTek, United States) was adopted to detect the OD values at 450 nm. These steps mentioned above were repeated at 0, 24, 48, 72, 96, and 120 h. Based on the OD values at 0 h, the relative absorbance was calculated.

Wound Healing Assay and Transwell for Migration Assay
In 24-well plates, we used serum-free RPMI 1640 medium to inoculate the cells. The scratch experiments were prepared when the cells were grown to 100% density, then utilized 10 µl pipette tips to create scratch wounds. The next, we took the images we need at 0, 24, and 48 h, which the area of wounds was quantified by ImageJ software. The transwell migration assay was described as follows: 4 × 10⁴ cells and 200 µl of serum-free culture medium were seeded on the upper transwell chambers, and in the lower chambers, there was 500 µl medium, that contained 20% FBS. It then took 20 h to incubate, after we relied on methanol to fix the cells which had migrated through membranes. For better counting under the light microscope, we added a staining step using 1% crystal violet as well.

Statistical Analyses
Except when publicly available databases and special software were used, the R software (version 4.0.3) helped us to perform graphical plots and general routine statistical analyses. Here, our prognostic model was constructed by some classical methods such as LASSO algorithm, univariate Cox regression, and multifactor Cox stepwise regression analysis method p < 0.05 was a signal that was considered to indicate statistical significance. Two-tailed Students’ t-test was used to analyze the difference between two subgroups in analysis of experiment results.

RESULTS
Correlation Statistics and Differences Analysis
The clinical information corresponding to TCGA samples is presented in Table 1, and the results of survival analysis of m6A regulatory genes have been uploaded as Supplementary File S1. Also, the corresponding survival curves are shown in Figure 1. Among them, IGFBP1, IGFBP2, IGFBP3, and FTO were high-risk prognostic factors for STAD. METTL3, WTAP, RBM15, RBM15B, YTHDC2, YTHDF2, HNRNPC, FMR1, LRPPRC, and RBMX were low-risk prognostic factors for STAD. The m6A prognostic network graph clearly showed co-expression relationships among most of the m6A regulatory genes, and positive correlations were predominant (Figure 2A). Similarly, in the co-expression network of m6A regulatory genes and immune genes (|correlation coefficient| > 0.6), HNRNPC, HNRNPA2B1, and LRPPRC had highly correlated co-expression relationships with most of the immune genes (Figure 2B). Finally, the heat map clearly showed the m6A-associated immune genes that were differentially expressed between the two groups ([logFC] > 0.5) & FDR <0.05 (Figure 2C).

The Prognostic Model, Mutation Results, and Dynamic Nomogram
Supplementary File S2 (containing training group), Supplementary File S3 (containing internal validation group) and Supplementary Files S4,5 (containing external validation group) are available as supplementary materials. We obtained the results of the univariate Cox analysis as follows. There were totals of 64 m6A-associated immune genes affecting prognosis. Using LASSO algorithms to help us remove highly correlated genes was extremely reliable, and after that we needed to build prognostic models using multivariate Cox stepwise regression, and for every
participant we calculated a risk score as follows: risk Score = 

\[-0.063^{*}RANGAP1 + 0.194^{*}GOPC +0.047^{*}PAEP + (-0.121)^{*}RAB19 + (-0.188)^{*}NHLRC3 + 0.027^{*}FZD6 + (-0.120)^{*}IDE\]

(Figures 3A–C; Table 2).

The median risk assessment was generated in the training group, and then the samples of the training groups, internal validation groups and external validation groups were subdivided into high and low-risk groups. Survival rates are variable, with the low-risk group being significantly higher than the high-risk group in all groups. The area under the ROC curve revealed extremely high predictive efficacy of our constructed prognostic model (Figure 4).

Mutation waterfall plots for both two groups intuitively showed that the genes, which own the highest mutation frequencies in both two risk groups were predominantly TTN, TP53, and MUC16 (Figures 5A,B). In addition, mutational load significantly affected the survival rate in participant in both two groups, enabling further refined stratification of prognosis (Figure 5C).

We created a web-based version of the Dynamic Column Plot APP (available at https://u20131050.shinyapps.io/STAD-m6A_ImmRNA-Dynamic_nomogram/) to enable direct online calculation of patient survival by entering the expression levels of model genes.

**Correlation of Clustering Type and Immune Microenvironment**

We classified TCGA samples into low-, and high-expression groups, and the classification is based on the prognostic impact of m6A-related immune genes. After our survival analysis study, these patients with high expression of m6A regulatory genes tended to have higher survival rates (Figure 6). The heat maps and violin plots of the tumor microenvironment showed that the m6A regulatory gene high-expression group had a higher tumor purity and lower level of immune cell infiltration in human tumors (Figure 7). The GSEA enrichment results reflected an important phenomenon in which low expression of immune genes was accompanied by the activation of an immunosuppressive function. This may be an important reason for that the low immune gene expression group showed a lower survival rate (Figure 8).

**Multi-Omics Analysis of Model Genes**

Based on our prognostic model, we further compared the correlations of all model genes with stem cell indices and tumor microenvironment parameters. Initial findings indicated that RANGAP1, GOPC, NHLRC3, FZD6, and IDE were significantly correlated with stem cell indices and tumor microenvironment parameters (Supplementary Figure 1). It is visualized from the multi-omics results that the CNV frequency and mutation frequency of the model genes were very low (Supplementary Figure 2). In particular, CNV in all model genes was able to affect the standard in tumor-infiltrating immune cells in STAD. Interestingly, only the infiltration level of Macrophage could affect the survival rate of STAD (Supplementary Figure 3). In addition, structural domain mutations were present in FZD6, IDE, PAEP, RAB19, and RANGAP1 (Supplementary Figure 4).

**Drug Sensitivity Analysis**

In the prognostic model, we performed drug sensitivity analysis separately for model genes and screened the top 16 drugs, and in

----

TABLE 1 | Clinical characteristics of STAD patients in the two databases.

| Characteristics | TCGA | | GEO1 | | GEO2 |
|----------------|------|---|------|---|------|
| **Total** | 338 | 100.00 | 367 | 100.00 | 76 | 100.00 |
| **Age (y)** | | | | | | |
| ≥65 | 189 | 55.92 | 128 | 35.85 | 38 | 50.00 |
| <65 | 149 | 44.08 | 229 | 64.15 | 38 | 50.00 |
| **Gender** | | | | | | |
| Male | 216 | 63.91 | 242 | 67.79 | 54 | 71.05 |
| Female | 122 | 36.09 | 115 | 32.21 | 22 | 28.95 |
| **Grade** | | | | | | |
| G1 | 7 | 2.07 | - | - | - | - |
| G2 | 116 | 34.32 | - | - | - | - |
| G3 | 215 | 63.61 | - | - | - | - |
| G4 | 0 | 0.00 | - | - | - | - |
| **Stage** | | | | | | |
| I | 42 | 12.43 | - | - | - | - |
| II | 112 | 33.14 | - | - | - | - |
| III | 153 | 45.27 | - | - | - | - |
| IV | 31 | 9.17 | - | - | - | - |
| **T stage** | | | | | | |
| T1 | 15 | 4.44 | 11 | 3.08 | 0 | 0.00 |
| T2 | 72 | 21.30 | 35 | 9.80 | 3 | 3.95 |
| T3 | 167 | 49.41 | 67 | 18.77 | 25 | 32.89 |
| T4 | 84 | 24.85 | 244 | 68.35 | 48 | 63.16 |
| **M stage** | | | | | | |
| M0 | 319 | 94.38 | - | - | - | - |
| M1 | 19 | 5.62 | - | - | - | - |
| **N stage** | | | | | | |
| N0 | 104 | 30.77 | 71 | 19.89 | 9 | 11.84 |
| N1 | 95 | 28.11 | 155 | 43.42 | 33 | 43.42 |
| N2 | 71 | 21.01 | 99 | 27.73 | 33 | 43.42 |
| N3 | 68 | 20.12 | 32 | 8.96 | 1 | 1.32 |
the model genes, these drugs were highly correlated with gene expression (Supplementary Figure 5A). We used these stomach adenocarcinoma drugs, such as cisplatin, doxorubicin, gemcitabine, and lapatinib, to elucidate the prognostic model associated with m6A, and these analyses helped us understand the clinical value of STAD treatment. The results showed that gemcitabine was more sensitive in the high-risk group (Supplementary Figure 5B).

Knockdown of RAB19’s Effects in Stomach Adenocarcinoma Cells Proliferation in Vitro

Firstly, we applied qRT-PCR to detect RAB19 mRNA expression, and in this study, SNU-216, N87 cells, and AGS cell lines were used. In our experiments, we obtained a higher expression of RAB19 in STAD cell lines SNU-216 and N87 than in normal gastric epithelial cells with GES1 (Figure 9A), and this is the reason why we selected them as subsequent knockdown experimental cell lines in vitro. In SNU-216 and N87 cells, RAB19 was knocked down. The material is siRNAs and transfection reagent. To ensure the reliability of the results, knockdown efficiency was examined by qRT-PCR (Figure 9B). We also performed CCK8 assays, an assay that explores the effects of RAB19 knockdown on the proliferation of STAD cells, and as a result, cells that underwent RAB19 knockdown (SNU-216 and N87 cells) had a more prominent proliferative capacity (Figure 9C). This was followed by the addition of wound-healing and transwell assays, which were used to investigate the effects of knockdown on cell migration. All experiments confirmed that knockdown increased the migratory capacity of SNU-216 cells (Figures 9D–G).
Overexpression of RAB19’s Effects in Stomach Adenocarcinoma Cells Proliferation in Vitro

Then, with the same method (qRT-PCR assay), we proceeded to examine the expression of RAB19 mRNA in STAD cell lines, including HGC-27, BGC-823, and SGC-7901. We found that the RAB19 in STAD cell lines (SGC-7901 and BGC-823) was presenting lower expression than in GES1 (Figure 10A), and this is the reason why we selected them as subsequent overexpression experimental cell lines in vitro. The efficiency of their overexpression of RAB19 was verified through qRT-PCR (Figure 10B). CCK8 experiments showed
that the proliferation (SGC-7901 and BGC-823 cells) was significantly decreased after RAB19 overexpression (Figure 10C). Subsequently, we also found that the migration ability was inhibited after RAB19 overexpression in these two cell lines (Figures 10D–G). Thus, RAB19 may be a protective factor that inhibits the migration and proliferation of STAD cells.

**DISCUSSION**

This discovery and comprehensive analysis of prognostic biomarkers can help clinicians to refine treatments and determine prognosis, as well as provides in-depth insights into the relevant pathophysiological mechanisms. Using various bioinformatics algorithms, we successfully developed a high-performance prognostic model based on the statistical
correlations between m6A-regulated genes and immune genes, with a corresponding web-based dynamic nomogram APP that enhanced the practical and translational significance of the model. Further, our results revealed the correlations between two typologies with the tumor microenvironment and m6A-score. Next, multi-omics analysis and drug sensitivity analysis targeting model genes enriched the study. Finally, knocking down and overexpressing RAB19 in STAD cell lines altered the proliferation and migration ability of the cells.

Research on big data provides unprecedented opportunities for biomedical development and enables to use many new technologies and methods for diseases treatment. For instance, gene therapy, gene diagnosis and targeted drugs. An increasing amount of clinical evidence demonstrates that in myeloproliferative neoplasms, advanced renal-cell carcinoma, gastric cancer, hepatocellular carcinoma, and aggressive prostate cancer, the combination of dependence on clinical data and genetic databases can provide individualized prediction of patient prognosis. It can also help in diagnosing and treating these patients (Grinfeld et al., 2018; Voss et al., 2018; Long et al., 2019; Kreuz et al., 2020; Zuo et al., 2020; Zhang et al., 2021a). Moreover, research in genetics has allowed us to better perform risk stratification of patients in clinical care (Nabors et al., 2020). In the case of STAD, a variety of prognostic models have been developed with wide application prospects (Shimura et al., 2022; Spolverato et al., 2022; Zhang et al., 2022). We have developed a high-performance prognostic model based on m6A-associated immune genes that has been successfully internally and externally validated and shows some degree of clinical translational value.

The model genes involved in this study, as high-risk independent prognostic factors for STAD, are currently

### Table 2

| Id    | Coef  | HR (95% CI) | P-value |
|-------|-------|-------------|---------|
| RANGAP1 | -0.0633837 | 0.93858324 (0.89445725, 0.98488608) | 0.00988514 |
| GOPC   | 0.19413485  | 1.21426002 (1.06250641, 1.387688) | 0.00437086 |
| PAEP   | 0.04719467  | 1.04832807 (1.0078499, 1.09042779) | 0.01881494 |
| RAB19  | -0.1209739  | 0.88605707 (0.7520692, 1.04391607) | 0.14812852 |
| NHLRC3 | -0.1875121  | 0.82901909 (0.68840239, 0.99835891) | 0.04900663 |
| FZD6   | 0.02671311  | 1.02707126 (1.00377194, 1.05091139) | 0.02251669 |
| IDE    | -0.1199501  | 0.8869647 (0.79426786, 0.99047995) | 0.03318732 |

### Figure 4

Clinical prognostic model evaluation (A) Training group (B) Internal validation group (C) External validation group, GSE84433_series_matrix.
available in published databases. The current study showed that RanGAP1 is dysregulated in a variety of cancers (Boudhraa et al., 2020). RANGAP1 is a nuclear transport protein, that is one of the components of the RanBP2 subcomplex, and the SUMO-ization of RanGAP1 is essential for its nuclear pore localization (He et al., 2021). In addition, RNA interference with RanGAP1 enhances DLBCL cell death and cell cycle arrest (Chang et al., 2013). It was found that the GTPase activity of Ras-related Ran can be induced by RanGAP (Bischoff et al., 1994). Ran expression has been verified to be higher in kidney, breast, colon, gastric, pancreatic, lung, and ovarian cancers than in normal groups (Abe et al., 2008; Barrès et al., 2010; Sheng et al., 2018; Lu et al., 2020). Moreover, Ran has been verified to be linked to higher grade, metastasis and local invasion in kidney, ovarian and breast cancers, and gastric cancer (Boudhraa et al., 2020; Lu et al., 2020). NHLRC3, a member of the miR-93-5p/17-5p/NHLRC3 axis, is also implicated in the progression of colon cancer, and it has even been reported to be an independent prognostic marker for colorectal cancer and a possible target for cancer therapy (Chen et al., 2017; Yang et al., 2022). Additionally, some
recent study showed using bioinformatics analysis that NHLRC3 correlates extremely well with the prognosis of gastric adenocarcinoma, and it play an important role the development of stomach cancer (Xu et al., 2016). FZD6, a member of the frizzled family, is a receptor for Wnts. There are numerous studies show that FZD6 expression is associated with the malignancy and prognosis of breast cancer, cervical cancer and human glioblastoma (Zhang et al., 2021b; Wang et al., 2021; Assidi et al., 2022). FZD6 also can inhibit the migration and proliferation of gastric cancer cells via targeting miR-21 to activate the non-classical Wnt pathway (Yan et al., 2016; Ko et al., 2022). The current research on RAB19 is not very clear.

**FIGURE 6** | Sample clustering based on m6A regulatory genes (A) Clustering heat map (B) Survival curve.
Some studies have reported that in colorectal cancer, RABs may play an important role in regulating cell cycle and immune-related pathways, and in gastric cancer, the miR495-5p/RAB19 axis inhibits its proliferation, migration, and invasion, so RAB19 perhaps be a potential biomarker for predicting the prognosis and immunotherapeutic response of related tumors (Hu and Ji, 2021; Jewett et al., 2021; Jiang et al., 2022). GOPC, a protein that containing a coiled helix motif, is also one of the prognostic markers of Early-Stage Lung Squamous Cell Carcinoma, and when fused with ROS1 and other ROS1, it can represent a rare but recurrent drug target in various glioma types (Li et al., 2021; Sievers et al., 2021). PAEP, a glycodelin gene, is connected with immune infiltration. It was identified in one study as an independent significant risk factor for Clear Cell Renal Cell Carcinoma (ccRCC) and as one of the survival predictive prognostic markers for melanoma (Sawyer, 2021; Wu et al., 2021; Zeng et al., 2022). IDE is a multifunctional protease whose main therapeutic areas are neuronal diseases and metabolism. However, the recent reports have indicated that it may be a potential target for cancer (Lesire et al., 2022). Actually, studies on the role of GOPC, PAEP and IDE in STAD are mostly lacking, but they all have important roles in other cancer types. Therefore, more preliminary single-gene bioinformatics analysis is needed to validate their functions in STAD (Yanti et al., 2008; Dydensborg et al., 2009; Ohara et al., 2017). These previous studies demonstrate, from a different perspective, that the inclusion of these seven modular genes in our signature is reasonable and reliable. In addition, our results suggest that RAB19, GOPC, PAEP, and IDE may be novel prognostic predictive genes for STAD. Furthermore, our study has shown that interfering with RAB19 expression improved the capacity of cell migration and cell proliferation and (SNU-216 and N87) in vitro, which was inversely validated by overexpression of RAB19, indicating the importance and potential role of RAB19.
in gastric adenocarcinoma. However, more researches are needed to further explore the specific mechanisms especially with RAB19 inhibits tumorigenesis development in STAD cells. Furthermore, the biofunction of seven prognosis-related m6A-associated immune genes in gastric adenocarcinoma remains largely unknown, with further studies on the effects of model genes on gastric adenocarcinoma needed. Future studies may focus on exploration of their potential mechanisms in STAD through molecular functional assays.

Based on the ssGSEA results and clustering grouping, the immune gene low-expression group accompanied by lower survival rates and a higher immune cell infiltration. In the tumor microenvironment, the multi-GSEA enrichment map provides a possible explanation for this higher degree of immune infiltration, which is accompanied by enhanced immunosuppressive activity, involving extensive regulation of multiple immune cell biological behaviors and multiple signaling pathways. Thus, it ultimately leads to a lower survival rate of patients.

Recent studies on m6A have revealed that it has key roles in various cancers. Inhibition of m6A-associated proteins effectively attenuates tumor cell self-renewal and overcomes

FIGURE 8 | Enrichment-related analysis (A) In the immune gene high-expression group, GO enrichment results showing GO terms were obviously enriched (B) In the immune gene high-expression group, KEGG enrichment results showing its pathways were obviously enriched.
methylating-agent-induced immune evasion, which provides an opportunity to develop effective targeted therapies (Su et al., 2020). Bo Zhang et al. showed that the effective immune infiltration was lacking in high m6A-score subtypes in STAD, and it was correlated with poor survival (Zhang et al., 2020). In vitro, m6A protein knockdown sensitized melanoma cells to IFNγ to promote the result of mouse’s anti-PD-1 inhibitors (Yang et al., 2019; Huang et al., 2020). Although there have been fewer m6A-related studies in STAD, the low m6A-related phenotype may provide obvious clinical benefits and therapeutic advantages. And in order to promote the efficacy of immunotherapy, we enhance the response to anti-PD-1/L1 immunotherapy and increase STAD neoantigen load (Zhang et al., 2020).

In combination with the co-expression network described above, these findings indicate that m6A-regulated genes and immune genes have extensive interactions in STAD and are closely associated with the suppression of immune activity. Thus, they are of biological importance.

In addition, in the high- and low-risk groups, the mutational load results were used to refine the survival stratification of STAD participants; this will help to determine the prognosis of patients.
more precisely. Also, multi-omics analysis of model of genes suggested that the expression levels of some model of genes and CNV could themselves influence immune cell infiltration in STAD. From the above, we can see the comprehensiveness and complexity of the factors regulating the tumor microenvironment.

FIGURE 10 | Overexpression of RAB19 inhibits migration and proliferation, in gastric tumor cells (A) In the STAD cell lines, SGC-7901, BGC-823, HGC-27, and normal gastric epithelial cell line GES1, the relative expression level was detected by RT-PCR (B) In the BGC-823 and SGC-7901 cell lines, the transfection efficiency of OE-RAB19 was detected by RT-PCR (C) In the BGC-823 and SGC-7901 cell lines, the effect of RAB19 overexpression on the proliferation was detected by the CCK-8 assay (D) Representative images from the wound healing assay (E) After overexpression of RAB19, the results of wound-healing assay were analysed (F, G) After overexpression of the RAB19, the transwell assay results were statistical analysed in the BGC-823 and SGC-7901 cell lines. ***p < 0.001, **p < 0.01, and *p < 0.05.
CONCLUSION
In summary, we have constructed a high-performance prognostic model for STAD and a corresponding web-based dynamic nomogram APP that enhances the model’s clinical significance. In addition, the correlations of Clustering Analysis and the tumor microenvironment provided further insight into the pathophysiological process of STAD. These results will help to improve the accuracy of prognosis of STAD patients, as well as providing new ideas and inspiration for more in-depth mechanistic studies. What’s more, in vitro, interference of RAB19 was shown to promote invasion and migration of gastric adenocarcinoma cells, while its overexpression inhibited these functions, suggesting a potential therapeutic role for RAB19 in stomach adenocarcinoma.

DATA AVAILABILITY STATEMENT
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

AUTHOR CONTRIBUTIONS
GH, QL, and YZ conceived of and designed the study. XL, WZ, XP, FY, and LS supervised the study and reviewed the manuscript. NL, MF, and YZ performed the literature search, generated the figures and tables, and wrote the manuscript, we confirm that the manuscript has been read and approved by all named authors.

REFERENCES
Abe, H., Kamai, T., Shirataki, H., Oyama, T., Arai, K., and Yoshida, K.-i. (2008). High Expression of Ran GTPase Is Associated with Local Invasion and Metastasis of Human Clear Cell Renal Cell Carcinoma. Int. J. Cancer 122 (10), 2391–2397. doi:10.1002/ijc.23400
Assidi, M., Buhmeida, A., Al-Zahrani, M. H., Al-Maghribi, J., Rasool, M., Naseer, M. I., et al. (2022). The Prognostic Value of the Developmental Gene FZD6 in Young Saudi Breast Cancer Patients: A Biomarkers Discovery and Cancer Inducers OncoScreen Approach. Front. Mol. Biosci. 9, 783735. doi:10.3389/fmolb.2022.783735
Atsavapranee, E. S., Billingsley, M. M., and Mitchell, M. J. (2021). Delivery Technologies for T Cell Gene Editing: Applications in Cancer Immunotherapy. EBioMedicine 67, 103354. doi:10.1016/j.ebiom.2021.103354
Barres, V., Ouellet, V., Lafontaine, J., Tonin, P. N., Provencher, D. M., and Mes-Masson, A.-M. (2010). An Essential Role for Ran GTPase in Epithelial Ovarian Cancer Cell Survival. Mol. Cancer 9, 272. doi:10.1186/1476-4598-9-272
Bischoff, F. R., Klebe, C., Kretschmer, J., Wittinghofer, A., and Ponstingl, H. (1994). RanGAP1 Induces GTPase Activity of Nuclear Ras-Related Ran. Proc. Natl. Acad. Sci. U.S.A. 91 (7), 2587–2591. doi:10.1073/pnas.91.7.2587
Boudhraa, Z., Carmona, E., Provencher, D., and Mes-Masson, A.-M. (2020). Ran GTPase: A Key Player in Tumor Progression and Metastasis. Front. Cell. Dev. Biol. 8, 345. doi:10.3389/fcell.2020.00345
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 68 (6), 394–424. doi:10.3322/caac.21492
Chang, K.-C., Chang, W.-C., Chang, Y., Hung, L.-Y., Lai, C.-H., Yeh, Y.-M., et al. (2013). Ran GTPase-Activating Protein 1 Is a Therapeutic Target in Diffuse Large B-Cell Lymphoma. PLoS One 8 (11), e79863. doi:10.1371/journal.pone.0079863

FUNDING
The National Natural Science Foundation of China (NSFC) (Grant No. 82003312,82173311). It plays an important role in supporting this study.

ACKNOWLEDGMENTS
We are grateful for the data support provided by the databases on the web, especially the TCGA, GEO, and GSEA databases. At the same time, we also appreciate the technical support by the Huazhong University of Science & Technology Analytical & Testing center technical support.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2022.935135/full#supplementary-material
Han, D., Liu, J., Chen, C., Dong, L., Liu, Y., Chang, R., et al. (2019). Anti-tumour Immunity Controlled through mRNA m6A Methylation and YTHDF1 in Dendritic Cells. *Nature* 566 (7743), 270–274. doi:10.1038/s41586-019-0911-x
He, L., Li, H., Wu, A., Peng, Y., Shu, G., and Yin, G. (2019). Functions of N6-Methyladenosine and its Role in Cancer. *Mol. Cancer* 18 (1), 176. doi:10.1186/s12943-019-1109-9
He, Y., Yang, Z., Zhao, C. S., Xiao, Z., Gong, Y., Li, Y. Y., et al. (2021). T-cell Receptor (TCR) Signaling Promotes the Assembly of RanBP2/RanGAP1-SUMO1/Ubch9 Nuclear Pore Supercomplex via PKC-B-Mediated Phosphorylation of RanGAP1. *eLife* 10. doi:10.7554/eLife.67123
Hu, N., and Ji, H. (2021). N6-methyladenosine (m6A)-Mediated Up-regulation of hHER2+ Tumors in hPD-1 Transgenic Mouse Model and Contributes Immune Antibody Drug Conjugate Combined with anti-PD-(L)1 Treatment Eliminates Single-Arm, Phase 2 Trial. *Oesophageal, Gastric, or Gastro-Oesophageal Junction Cancer: an Open-Label, C.* et al. (2020). First-line Pembrolizumab and Trastuzumab in HER2-Positive Breast Cancer. *Breast Cancer Res. Treat.* 61. doi:10.1007/s10515-018-01853-x
Luo et al. m6A-Associated Immune Signature for STAD
Lu, J., Wang, Y.-h., Yoon, C., Huang, X.-y., Xu, Y., Xie, J.-w., et al. (2020). Circular RNA Circ-RanGAP1 Regulates VEGA Expression by Targeting mir-877-3P to Facilitate Gastric Cancer Invasion and Metastasis. *Cancer Lett.* 471, 38–48. doi:10.1016/j.canlet.2019.11.038
Mo, P., Xie, S., Cai, W., Ruan, J., Du, Q., Ye, J., et al. (2020). N(6)-methyladenosine (m(6)A) RNA Methylation Signature as a Predictor of Stomach Adenocarcinoma Outcomes and its Association with Immune Checkpoint Molecules. *J. Int. Med. Res.* 48 (9), 300065209310450. doi:10.1177/0300067220918105
Nabors, L. B., Portnow, J., Ahluwalia, M., Baehring, J., Brem, H., Brem, S., et al. (2020). Central Nervous System Cancers. Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. *J. Natl. Compr. Cancer Netw.* 18 (11), 1537–1570. doi:10.6004/jnccn.2020.0052
Noguchi, Y., Yoshikawa, T., Tsuburaya, A., Motohashi, H., Karpeh, M. S., and Brennan, M. F. (2000). Is Gastric Carcinoma Different between Japan and the United States? *Cancer* 89 (11), 2237–2246. doi:10.1002/1097-0142(20001201)89:11<2237::AID-CNCR213.0.CO;2-9
O’Donnell, J. S., Teng, M. W. L., and Smyth, M. J. (2019). Cancer Immunoeediting and Resistance to T Cell-Based Immunotherapy. *Nat. Rev. Clin. Oncol.* 16 (3), 151–167. doi:10.1038/s41575-018-0142-2
Ohara, N., Haraguchi, N., Koseki, J., Nishizawa, Y., Kawai, K., Takahashi, H., et al. (2017). Low Expression of the GOPO Is a Poor Prognostic Marker in Colorectal Cancer. *Oncol. Lett.* 14 (4), 4483–4490. doi:10.3892/ol.2017.6817
Sawyer, L. (2021). β-Lactoglobulin and Glycodulin: Two Sides of the Same Coin? *Front. Physiol.* 12, 678080. doi:10.3389/fphys.2021.678080
Sheng, C., Qiu, J., Wang, Y., He, Z., Wang, H., Wang, Q., et al. (2018). Knockdown of Ran GTase Expression Inhibits the Proliferation and Migration of Breast Cancer Cells. *Mol. Med. Rep.* 18 (1), 157–168. doi:10.3892/mmr.2018.8952
Shimura, T., Kandimalla, R., Okugawa, Y., Ohi, M., Toyama, Y., He, C., et al. (2022). Novel Evidence for m6A Methylation Regulators as Prognostic Biomarkers and FTO as a Potential Therapeutic Target in Gastric Cancer. *Br. J. Cancer* 126 (2), 228–237. doi:10.1038/s41416-021-01581-w
Sievers, P., Stichel, D., Sill, M., Schrimpf, D., Sturm, D., Selt, F., et al. (2021). GOPC: ROS1 and Other ROS1 Fusions Represent a Rare but Recurrent Drug Target in a Variety of Glioma Types. *Acta Neuropathol.* 142 (6), 1065–1069. doi:10.1007/s00401-021-02869-1
Smyth, E. C., Nilsson, M., Grabbsch, H. L., van Grieken, N. C., and Lordick, F. (2020). Gastric Cancer. *Lancet Oncol.* 12, 629–635. doi:10.1016/S1470-2045(20)30169-8
Song, Z., Wu, Y., Yang, J., Yang, D., and Fang, X. (2017). Progress in the Treatment of Advanced Gastric Cancer. *Vacuna* 19 (3), 101042831714626. doi:10.1177/101042831714626
Spolverato, G., Capelli, G., Lorenzoni, G., Gregori, D., Squires, M. H., Poultsides, G. A., et al. (2022). Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-free Survival after Curative-Intent Gastroenterostomy for Gastric Cancer. *Ann. Surg. Oncol.* 29 (2), 1220–1229. doi:10.1245/s10434-021-10768-7
Su, R., Dong, L., Li, Y., Gao, M., Han, L., Wunderlich, M., et al. (2020). Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. *Cancer Cell* 38 (1), 79–96. doi:10.1016/j.ccell.2020.04.017
Thompson, E. D., Zahurak, M., Murphy, A., Cornish, T., Cuka, N., Abdelfatah, E., et al. (2010). Chemotherapy for Advanced Gastric Cancer. *Cancer Lett.* 471, 38–48. doi:10.1016/j.cancert.2010.06.011
Voss, M. H., Reising, A., Cheng, Y., Patel, P., Marker, M., Kuo, F., et al. (2018). Genomically Annotated Risk Model for Advanced Renal-Cell Carcinoma: a Retrospective Cohort Study. *Lancet Oncol.* 19 (12), 1688–1698. doi:10.1016/s1470-2045(18)30648-x
Vu, L. P., Pickering, B. F., Cheng, Y., Zaccara, S., Nguyen, D., Minuesa, G., et al. (2017). The N6-Methyladenosine (m6A)-Forming Enzyme METTL3 Controls Myeloid Differentiation of Normal Hematopoietic and Leukemia Cells. *Nat. Med.* 23 (11), 1369–1376. doi:10.1038/nm.4416
Wagner, A. D., Unverzagiz, S., Grothe, W., Kleber, G., Grothey, A., Haerting, J., et al. (2010). Chemotherapy for Advanced Gastric Cancer. *Gastrointestinal Cancer*. Rev. 3, eCD004064. doi:10.1002/14651858.CD004064.pub3
Wang, H., Xu, T., Huang, Q., Jin, W., and Chen, J. (2020). Immunotherapy for Malignant Glioma: Current Status and Future Directions. *Trends Pharmacol. Sci.* 41 (2), 123–138. doi:10.1016/j.tips.2019.12.003
Wang, Q., Chen, D., Ding, Q., Zhao, Y., Wang, Z., Chen, J., et al. (2020). METTL3-mediated m6A Modification of HDGF mRNA Promotes Gastric Cancer
Progression and Has Prognostic Significance. Gut 69 (7), 1193–1205. doi:10.1136/gutjnl-2019-319639

Wang, Y. Q., Zhang, Q. Y., Li, Q. X., Zhang, J., and Zhang, J. W. (2020). Clinicopathological and Immunological Characterization of RNA M(6)A Methylation Regulators in Ovarian Cancer. Mol. Genet. Genom Med.

Wang, T., Li, W., Ye, B., Zhang, S., Lei, X., and Zhang, D. (2021). FTO-stabilized IncRNA HOXC13-AS Epigenetically Upregulated FZD6 and Activated Wnt/beta-Catenin Signaling to Drive Cervical Cancer Proliferation, Invasion, and EMT. J. BUON official J. Balkan Union Oncol. 26 (4), 1279–1291.

Weng, Y.-L., Wang, X., An, R., Cassin, J., Vissers, C., Liu, Y., et al. (2018). Epitranscriptomic m6A Regulation of Axon Regeneration in the Adult Mammalian Nervous System. Neuron 97 (2), 313–325. doi:10.1016/neuron.2017.12.036

Wu, L., Hu, X., Dai, H., Chen, K., and Liu, B. (2021). Identification of an m6A Regulators-Mediated Prognosis Signature for Survival Prediction and its Relevance to Immune Infiltration in Melanoma. Front. Cell. Dev. Biol. 9, 718912. doi:10.3389/fcell.2021.718912

Xie, J.-W., Huang, X.-B., Chen, Q.-Y., Ma, Y.-B., Zhao, Y.-J., Liu, L.-C., et al. (2020). m6A Modification-Mediated BATF2 Acts as a Tumor Suppressor in Gastric Cancer through Inhibition of ERK signaling. A Modification-Mediated BATF2 Acts as a Tumor Suppressor in Gastric Cancer through Inhibition of ERK Signaling. Mol. Cancer 19 (1), 114. doi:10.1186/s12943-020-01223-4

Xu, G., Li, K., Zhang, N., Zbu, B., and Feng, G. (2016). Screening Driving Transcription Factors in the Processing of Gastric Cancer. Gastroenterol. Res. Pract. 2016, 8431480. doi:10.1155/2016/8431480

Xu, S., Tang, L., Dai, G., Luo, C., and Liu, Z. (2020). Expression of m6A Regulators Correlated with Immune Microenvironment Predicts Therapeutic Efficacy and Prognosis in Gliomas. Front. Cell. Dev. Biol. 8, 594112. doi:10.3389/fcell.2020.594112

Yadav, P. K., Rajvanshi, P. K., and Rajasekharan, R. (2018). The Role of Yeast m6A Methyltransferase in Peroxisomal Fatty Acid Oxidation. Curr. Genet. 64 (2), 417–422. doi:10.1007/s00294-017-0769-5

Yan, F., Al-Kali, A., Zhang, Z., Liu, J., Pang, J., Zhao, N., et al. (2018). A Dynamic N6-Methylenadenosine Methylome Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors. Cell. Res. 28 (11), 1062–1076. doi:10.1038/s41422-018-0097-4

Yan, J., Liu, T., Zhou, X., Dang, Y., Yin, C., and Zhang, G. (2016). FZD6, Targeted by miR-21, Represses Gastric Cancer Cell Proliferation and Migration via Activating Non-canonical Wnt Pathway. Am. J. Transl. Res. 8 (5), 2354–2364.

Yang, L., Yang, T., Wang, H., Dou, T., Fang, X., Shi, L., et al. (2022). DNMBP-AS1 Regulates NHLRC3 Expression by Sponging miR-93-5p/17-5p to Inhibit Colon Cancer Progression. Front. Oncol. 12, 765163. doi:10.3389/fonc.2022.765163

Yang, S., Wei, J., Cui, Y.-H., Park, G., Shah, P., Deng, Y., et al. (2019). m6A mRNA Demethylation FTO Regulates Melanoma Tumorigenicity and Response to Anti-PD-1 blockade. m6A mRNA Demethylation FTO Regulates Melanoma Tumorigenicity and Response to Anti-PD-1 Blockade. Nat. Commun. 10 (1), 2782. doi:10.1038/s41467-019-10669-0

Yang, Z., Jiang, X., Li, D., and Jiang, X. (2020). HRXIP Promotes Gastric Cancer via METTL3-Mediated MYC mRNA m6A Modification. Aging 12 (24), 24967–24982. doi:10.18632/aging.103767

Yfanti, C., Menegle, K., Gkazepis, A., Weirich, G., Giereig, C., Kuo, W. L., et al. (2008). Expression of Metalloprotease Insulin-Degrading Enzyme Insulin in Normal and Malignant Human Tissues. Int. J. Mol. Med. 22 (4), 421–431.

Zaccara, S., Ries, R. J., and Jaffrey, S. R. (2019). Reading, Writing and Erasing mRNA Methylation. Nat. Rev. Mol. Cell. Biol. 20 (10), 608–624. doi:10.1038/s41580-019-0168-5

Zeng, X., Li, L., Hu, Z., and Peng, D. (2022). Integrated Multi-Omics Analysis Identified PTPRG and CHL1 as Key Regulators of Immunophenotypes in Clear Cell Renal Cell Carcinoma (cRCC). Front. Oncol. 12, 832027. doi:10.3389/fonc.2022.832027

Zhang, B., Wu, Q., Li, B., Wang, D., Wang, L., Zhou, Y. L., et al. (2020). m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Gastric Cancer. Mol. Cancer 19 (1), 53. doi:10.1186/s12943-020-01170-0

Zhang, C., Yang, J., Chen, Y., Jiang, F., Liao, H., Liu, X., et al. (2022). mRNAs Derived from Plasma Small Extracellular Vesicles Predict Organo-Tropic Metastasis of Gastric Cancer. Gastric Cancer 25 (2), 360–374. doi:10.1007/s10120-021-01267-5

Zhang, C., Zhang, M., Ge, S., Huang, W., Lin, X., Gao, J., et al. (2019). Reduced m6A Modification Predicts Malignant Phenotypes and Augmented Wnt/PI3K-Akt Signaling in Gastric Cancer. Cancer Med. 8 (10), 4766–4781. doi:10.1002/cam4.2360

Zhang, D., Ma, S., Zhang, C., Li, P., Mao, B., Guan, X., et al. (2021). MicroRNA-935 Directly Targets FZD6 to Inhibit the Proliferation of Human Glioblastoma and Correlate to Glioma Malignancy and Prognosis. Front. Oncol. 11, 566492. doi:10.3389/fonc.2021.566492

Zhang, Y., Jiang, J., Zhang, J., Shen, H., Wang, M., Guo, Z., et al. (2021). CircDIDO1 Inhibits Gastric Cancer Progression by Encoding a Novel DIDO1-529aa Protein and Regulating PRDX2 Protein Stability. Mol. Cancer 20 (1), 101. doi:10.1186/s12943-021-01390-y

Zuo, X., Chen, Z., Gao, W., Zhang, Y., Wang, J., Wang, J., et al. (2020). M6A-mediated Upregulation of LINC00958 Increases Lipogenesis and Acts as a Nanotherapeutic Target in Hepatocellular Carcinoma. J. Hematol. Oncol. 13 (1), 5. doi:10.1186/s13045-019-01839-x

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Luo, Fu, Zhang, Li, Zha, Yang, Chen, Mei, Peng, Shen, Zhang, Li and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.